Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Oxysterols are a diverse class of 27-carbon oxygenated derivatives of cholesterol that serve as crucial bioactive lipids and signaling molecules in human physiology [2, 11]. They are produced through enzymatic oxidation via cytochrome P450 enzymes—such as sterol 27-hydroxylase (CYP27A1) and cholesterol 24-hydroxylase (CYP46A1)—or non-enzymatically through reactive oxygen species [2, 4]. Biologically, oxysterols function as endogenous ligands for various receptors, including the Liver X Receptors (LXRα and LXRβ), Retinoic acid-related Orphan Receptors (RORs), and the G-protein coupled receptor EBI2 (GPR183), thereby regulating lipid metabolism, immune cell migration, and inflammatory responses [1, 7, 13]. Pathologically, they are implicated in the progression of atherosclerosis, neurodegenerative diseases like Alzheimer's, and certain cancers, where they can act as selective estrogen receptor modulators (SERMs) or pro-inflammatory mediators [6, 9, 11]. Therapeutic strategies involving oxysterols focus on modulating their biosynthetic enzymes or targeting their receptors; for instance, semi-synthetic oxysterol analogues like Oxy133 and Oxy210 are under development for bone regeneration and anti-inflammatory applications, respectively [3, 15, 23]. However, drug development in this area faces challenges such as the potential for off-target LXR activation leading to hepatic steatosis and the complex, often opposing biological effects of different oxysterol species [18, 19].
As bioactive ligands, oxysterols modulate cellular physiology through the activation or inhibition of nuclear receptors such as Liver X Receptors (LXR) and Retinoic acid-related Orphan Receptors (ROR), as well as G-protein coupled receptors like EBI2 [1, 7, 13]. They also serve as precursors to bile acids and play a critical role in the feedback inhibition of cholesterol biosynthesis by promoting the degradation of HMG-CoA reductase and regulating SREBP maturation via interaction with Insig proteins [16, 21, 22].
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Oxysterols (OHCs).